Relay Therapeutics
Relay Therapeutics is a Cambridge, Massachusetts clinical-stage precision medicines company (NASDAQ: RLAY) using protein motion to drug historically intractable oncology and genetic-disease targets. Its Dynamo platform combines full-length protein engineering, cryo-EM, ambient-temperature X-ray crystallography, long-timescale molecular dynamics, machine learning, virtual screening, activity- and ligand-based screening, and an ML-powered DNA-encoded library (REL-DEL) to design molecules against conformational states that static structures miss. The clinical pipeline is led by zovegalisib (RLY-2608), described as the first allosteric, pan-mutant, isoform-selective PI3K-alpha inhibitor, in Phase 3 for HR+/HER2- breast cancer and Phase 1/2 for vascular anomalies and PROS; RLY-8161, an NRAS- selective inhibitor, is in Phase 1/2 for NRAS-mutant solid tumors; an alpha-galactosidase A non-inhibitory chaperone for Fabry disease is in discovery; lirafugratinib (RLY-4008, FGFR2) was out-licensed to Elevar Therapeutics in December 2024. Relay has no public developer API, SDK, or open-source release; the Dynamo platform is proprietary internal R&D tooling, and the company's GitHub organization currently has no public repositories. The commercial surface is therapeutic candidates, clinical partnerships, and out-licensing rather than data products.
Index entry only — little beyond a description and a link, and nothing machine-readable enough for an agent to act on without a human reading the site first.
API Evangelist profiles Relay Therapeutics the way a machine reads it — 1 machine-readable artifact, pulled from the provider's own public surface and indexed so a developer, an analyst, or an AI agent can evaluate it against every other provider on the network.
Every provider in the network is reduced to the same set of machine-readable artifacts — OpenAPI contracts, event specifications, GraphQL schemas, runnable collections, pricing and rate-limit signals, security posture, OAuth scopes, and the agent surfaces (MCP servers and skills) that let software drive the API on its own. We profile them because the interface is the part of a company you can actually inspect: it is a truer signal of what a provider does than any marketing page. From those artifacts we compute the Kin Score — Relay Therapeutics scores 7.4/100 (minimal), with a separate agent-readiness read of 0/100 (human only). The full breakdown is below, followed by every artifact we hold — each card links through to its machine-readable definition on apis.io.
Kin Score
This is the API Evangelist rating — a single, repeatable read computed from the artifacts on this page. Green fill is points earned; the red track is points possible, so every bar shows earned-versus-possible at a glance.
Kin Score
How this is scored →scored 2026-07-27 · rubric v0.5
How we profile Relay Therapeutics
Each block below is one kind of artifact we hold for Relay Therapeutics. For each we say what it is and why it earns a place in the profile, then list every one we've indexed — capped at two rows, scroll within the panel for the rest.
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals — the evidence that a provider takes security seriously enough to document it. We profile it because you can't govern what you can't see.
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Every other property we hold for Relay Therapeutics — documentation, portals, status pages, policies, and corporate surface — grouped by the job it does, following the integrator's arc from getting started to running in production.
Build 1
SDKs, sample code, and the tooling you integrate with
Access & Security 1
Authentication, authorization, and security posture
Operate 1
Status, limits, changes, and where to get help
Company 5
The organization behind the API
Other 5
Properties that don't map to a standard resource type
← All providers · Data indexed from github.com/api-evangelist/relay-tx · machine-readable index on apis.io